Public Alert No. 037/2026 – Alert on Suspected Counterfeit Pulmicort® (Budesonide) Inhalation Suspension
The National Agency for Food and Drug Administration and Control (NAFDAC) is informing the public of the detection of a suspected counterfeit medicinal product found in the Nigerian market that infringes on the approved marketing authorization of Pulmicort® (Budesonide) manufactured by AstraZeneca. The information was provided to NAFDAC by AstraZeneca following market surveillance activities. AstraZeneca […]
Public Alert No. 036/2026 – Alert on Suspected Counterfeit Products Mimicking Forxiga® (Dapagliflozin)
The National Agency for Food and Drug Administration and Control (NAFDAC) is informing the public of the detection of suspected counterfeit medicinal products found in the Nigerian market that infringe on the approved marketing authorization of Forxiga® (dapagliflozin) manufactured by AstraZeneca. AstraZeneca notified NAFDAC following market surveillance activities which identified products bearing names closely resembling […]
Public Alert No. 035/2026 – Alert on the Marketing and Sale of Unregistered Menofix Composition
The National Agency for Food and Drug Administration and Control (NAFDAC) is alerting the public about the marketing and sale of unregistered Menofix Composition. NAFDAC received a complaint concerning the marketing and sale of Menofix Capsules. The complainant also raised concerns regarding possible liver-related adverse effects associated with some of the ingredients contained in the […]
